查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363998

全球生物製药市场2023-2030

Global Biopharmaceuticals Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 250 Pages | 商品交期: 2-3个工作天内

价格

细分市场前景

全球生物製药市场按产品类型、服务和应用细分。根据产品类型，市场细分为单株抗体、重组生长因子、纯化蛋白、疫苗、荷尔蒙、基因疗法和其他（干扰素、合成免疫调节剂）。根据服务，市场分为实验室测试、客户专有测试以及药典和多药典实验室测试。此外，根据应用，市场细分为肿瘤学、发炎和传染病、自体免疫疾病、代谢性疾病、心血管疾病、神经系统疾病和其他（荷尔蒙失调）。在这些应用中，由于肿瘤药物的开发不断增长，包括标靶治疗、化疗药物、免疫疗法和荷尔蒙疗法等多种药物，预计肿瘤细分市场将占据相当大的市场份额。癌症。

预计疫苗细分市场将在全球生物製药市场中占据相当大的份额

在产品类型中，疫苗细分市场预计将在全球生物製药市场中占据相当大的份额。这一细分市场的成长归因于疫苗开发过程中奈米技术、基于基因的检测、下一代定序技术和基因工程的整合的增加，预计将增强新型疫苗类型的革命性潜力。核酸疫苗、mRNA疫苗、载体疫苗和生物材料疫苗是疫苗革命的最新趋势，因为它们具有解决现有技术问题的潜力。例如，2023年9月，辉瑞公司和BioNTech SE宣布，美国FDA批准了针对12岁及以上个人的补充生物製剂许可申请，​​并为该公司的Omicron XBB授予6个月至11岁个人的紧急使用授权.1.5 适应的单价COVID-19 疫苗。

区域展望

全球生物製药市场根据地理位置进一步细分，包括北美（美国和加拿大）、欧洲（英国、义大利、西班牙、德国、法国和欧洲其他地区）、亚太地区（印度、中国、日本、韩国、亚洲其他地区）以及世界其他地区（中东和非洲以及拉丁美洲）。其中，亚太地区由于强劲的市场份额，预计将在全球市场中占据显着份额。医疗设施基础，以及专门针对这些复杂疾病的根本原因的先进治疗方案的可用性，改善的治疗结果，并加强该地区的患者护理。

北美地区预计全球生物製药市场复合年增长率显着成长

在所有地区中，北美地区预计在预测期内将以相当大的复合年增长率成长。区域增长归因于用于疾病治疗的生物製药的采用和可用性的增加以及疾病诊断意识的提高。随着经济成长、医疗保健提供和保险机制的扩大，对本地和进口药品的需求增加。根据欧洲製药工业协会联合会（EFPIA）2022年5月的数据，2021年北美占全球药品销售额的49.1%，而欧洲为23.4%。随着新兴市场越来越多地应对在更强大的经济体中已经普遍存在的非传染性疾病（NCD），包括糖尿病和高血压，而困扰许多新兴市场的传染性疾病（如后天免疫缺陷综合症、疟疾和结核病）持续存在，药品需求呈现多样性。全球人口的成长也促进了药品消费。

市场成长受到多种因素的推动，例如老年人口的增加、癌症和糖尿病等慢性病盛行率的激增以及全球生物製药采用的增加。此外，预计生物製药公司之间策略合作的增加也将补充生物製药产业的成长。主要市场参与者包括艾伯维公司、阿斯特捷利康公司、罗氏公司、默克公司、辉瑞公司等。

市场参与者展望

服务生物製药市场的主要公司包括罗氏公司、强生公司、艾伯维公司、默克公司、诺华公司、辉瑞公司等。市场参与者透过各种策略（包括併购、合作、合作、融资和新产品发布），为市场成长做出了巨大贡献，以保持市场竞争力。例如，2020 年 10 月，IAVI（一个致力于解决紧迫的、未解决的全球健康挑战的非营利科学研究组织）和印度血清研究所 Pvt.疫苗和生物製品製造商有限公司宣布与德国达姆施塔特的科技公司默克达成协议，开发新冠病毒 (COVID-19) 中和单株抗体 (mAb)。

报告涵盖：

  • 2022年市场价​​值资料分析及2030年预测。
  • 每个细分市场的年化市场收入（百万美元）。
  • 主要地理区域的国家分析。
  • 全球生物製药市场的主要公司。根据现有资料，报告中还提供了与新产品发布相关的资讯以及相关新闻。
  • 透过确定未来强劲成长的关键细分市场来分析业务策略。
  • 市场进入和市场扩张策略分析。
  • 透过识别市场中「谁的立场」来制定竞争策略。

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • AbbVie, Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Johnson and Johnson Service, Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Pfizer, Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • F. Hoffman-La Roche, Ltd.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 按产品类型分類的全球生物製药市场
    • 单株抗体
    • 重组生长因子
    • 纯化蛋白质
    • 疫苗
    • 荷尔蒙
    • 基因疗法
    • 其他（干扰素、合成免疫调节剂）
  • 全球生物製药市场（按服务）
    • 实验室测试
    • 客户专有测试
    • 药典和多药典实验室测试
  • 全球生物製药市场按应用
    • 肿瘤学
    • 发炎和传染病
    • 自体免疫疾病
    • 代谢紊乱
    • 心血管疾病
    • 神经系统疾病
    • 其他（荷尔蒙失调）

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区
    • 拉丁美洲
    • 中东和非洲

第 6 章：公司简介

  • AbbVie Inc.
  • Bayer AG
  • Abbott Laboratories
  • Allergan, Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • bioMerieux SA
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • GlaxoSmithKline PlcPharmaceuticals Ltd.
  • McKesson Corp.
  • Moderna, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Sanofi SA
  • Takeda Pharmaceutical Industries, Ltd.
  • Vertex Pharmaceuticals
Product Code: OMR2027725

Title: Global Biopharmaceuticals Market Size, Share & Trends Analysis Report by Product Type (Monoclonal Antibodies, Recombinant Growth Factors, Purified Proteins, Vaccines, Hormones, Gene Therapies and Others), by Service (Laboratory Testing, Customer Proprietary Testing, Compendial and Multi Compendial Laboratory Testing), and by Application (Oncology, Inflammatory and Infectious Diseases, Autoimmune Disorders, Metabolic Disorders, Cardiovascular Diseases, Neurological Diseases and Other),Forecast Period (2023-2030).

Global biopharmaceuticals market is anticipated to grow at a CAGR of 7.2 % during the forecast period (2023-2030). Chronic diseases such as cancer, autoimmune disorders, diabetes, and cardiovascular diseases continue to rise globally. Biopharmaceutical consumption globally growing, partly driven by a growing need for drugs to treat aging-related and chronic diseases. The growing adoption of technological advancement for drug discovery in complex diseases is the key factor supporting the growth of the market globally. According to the World Health Organization (WHO), in August 2023, HPV infection caused about 5.0% of all cancers globally, with an estimated 625 600 women and 69 400 men getting HPV-related cancer each year. Women living with human immunodeficiency virus (HIV) are six times more likely to develop cervical cancer compared to women without HIV. Cervical cancer is often curable when detected early and effectively managed, but treatment options are more limited in advanced stages. Market players are continuously focusing on the introduction of drugs for chronic diseases. For instance, in November 2022, Regeneron Pharmaceuticals, Inc. announced that the European Commission (EC) approved Libtayo® (cemiplimab) as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Segmental Outlook

The global biopharmaceuticals market is segmented by product type, service, and application. Based on the product type, the market is sub-segmented into monoclonal antibodies, recombinant growth factors, purified proteins, vaccines, hormones, gene therapies, and others (interferon, synthetic immunomodulators). Based on the service, the market is sub-segmented into laboratory testing, customer proprietary testing, and compendial and multi-compendial laboratory testing. Further, based on application, the market is sub-segmented into oncology, inflammatory and infectious diseases, autoimmune disorders, metabolic disorders, cardiovascular diseases, neurological diseases, and other (hormonal disorders). Among the applications, the oncology sub-segment is anticipated to hold a considerable share of the market owing to the rise in the development of oncology drugs including a wide range of medications such as targeted therapies, chemotherapy agents, immunotherapies, and hormone therapies to treat cancer.

The Vaccines Sub-Segment is Anticipated to Hold a Considerable Share of the Global Biopharmaceuticals Market

Among the product types, the vaccines sub-segment is expected to hold a considerable share of the global biopharmaceutical market. The segmental growth is attributed to an increase in the integration of nanotechnology, gene-based assays, next-generation sequencing technologies, and genetic engineering in the process of vaccine development is expected to enhance the revolutionary potential of novel vaccine types. Nucleic acid vaccines, mRNA vaccines, vector vaccines, and biomaterial-based vaccines are recent trends in the revolutionization of vaccines based on their potential to address issues of existing technology. For instance, in September 2023, Pfizer Inc. and BioNTech SE announced that the US FDA approved the supplemental biologics license application for individuals 12 years and older and granted emergency use authorization for individuals 6 months through 11 years of age for the companies' Omicron XBB.1.5-adapted monovalent COVID-19 vaccine.

Regional Outlook

The global biopharmaceuticals market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to a strong base of healthcare facilities, and the availability of advanced treatment options that specifically target the underlying causes of these complex diseases, improved therapeutic outcomes, and enhanced patient care in this region.

The North American region is Expected to Grow at a Significant CAGR in the Global Biopharmaceuticals Market

Among all regions, the North American region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to a rise in the adoption and availability of biopharmaceuticals for disease treatment and a surge in disease diagnosis awareness. Demand for local and imported pharmaceutical products increased as economies grew, and healthcare provision and insurance mechanisms expanded. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), in May 2022, in 2021 North America accounted for 49.1% of global pharmaceutical sales compared with 23.4% for Europe. the diversity of pharmaceutical needs as emerging markets increasingly address noncommunicable diseases (NCDs) already prevalent in stronger economies, including diabetes and hypertension, while communicable diseases that afflict many emerging markets such as acquired immunodeficiency syndrome, malaria, and tuberculosis persist. The increase in the global population is also contributing to pharmaceutical consumption.

The market growth is driven by various factors, such as an increase in the elderly population, a surge in the prevalence of chronic diseases such as cancer and diabetes, and an increase in the adoption of biopharmaceuticals globally. Furthermore, a rise in strategic collaborations among biopharmaceutical companies is also anticipated to supplement the growth of the biopharmaceutical industry. The key market player includes AbbVie Inc., AstraZeneca plc, F. Hoffmann-La Roche AG, Merck & Co., Inc., Pfizer Inc. and others.

Market Players Outlook

The major companies serving the biopharmaceuticals market include F. Hoffmann-La Roche AG, Johnson & Johnson, AbbVie, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in October 2020, IAVI, a nonprofit scientific research organization addressing urgent, unmet global health challenges, and Serum Institute of India Pvt. Ltd., a manufacturer of vaccines and biologics, announced an agreement with Merck KGaA, Darmstadt, Germany, a science and technology company, to develop COVID-19 neutralizing monoclonal antibodies (mAbs).

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global biopharmaceuticals market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. AbbVie, Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Johnson and Johnson Service, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Pfizer, Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. F. Hoffman-La Roche, Ltd.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Biopharmaceuticals Market by Product Type
    • 4.1.1. Monoclonal Antibodies
    • 4.1.2. Recombinant Growth Factors
    • 4.1.3. Purified Proteins
    • 4.1.4. Vaccines
    • 4.1.5. Hormone
    • 4.1.6. Gene Therapies
    • 4.1.7. Other (Interferon, Synthetic Immunomodulators)
  • 4.2. Global Biopharmaceuticals Market by Service
    • 4.2.1. Laboratory Testing
    • 4.2.2. Customer Proprietary Testing
    • 4.2.3. Compendial and Multi Compendial Laboratory Testing
  • 4.3. Global Biopharmaceuticals Market by Application
    • 4.3.1. Oncology
    • 4.3.2. Inflammatory and Infectious Diseases
    • 4.3.3. Autoimmune Disorders
    • 4.3.4. Metabolic Disorders
    • 4.3.5. Cardiovascular Diseases
    • 4.3.6. Neurological Diseases
    • 4.3.7. Other(Hormonal Disorders)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World
    • 5.4.1. Latin America
    • 5.4.2. Middle East and Africa

6. Company Profiles

  • 6.1. AbbVie Inc.
  • 6.2. Bayer AG
  • 6.3. Abbott Laboratories
  • 6.4. Allergan, Inc.
  • 6.5. Amgen Inc.
  • 6.6. AstraZeneca plc
  • 6.7. Bayer AG
  • 6.8. Biogen Inc.
  • 6.9. bioMerieux SA
  • 6.10. Bristol-Myers Squibb
  • 6.11. Eli Lilly and Company
  • 6.12. GlaxoSmithKline PlcPharmaceuticals Ltd.
  • 6.13. McKesson Corp.
  • 6.14. Moderna, Inc.
  • 6.15. Merck & Co., Inc.
  • 6.16. Novartis AG
  • 6.17. Novo Nordisk A/S
  • 6.18. Sanofi SA
  • 6.19. Takeda Pharmaceutical Industries, Ltd.
  • 6.20. Vertex Pharmaceuticals

LIST OF TABLES

  • 1. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL RECOMBINANT GROWTH FACTORS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL PURIFIED PROTEINS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL HORMONE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL GENE THERAPIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL OTHER BIOPHARMACEUTICALS PRODUCTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY SERVICE, 2022-2030 ($ MILLION)
  • 10. GLOBAL BIOPHARMACEUTICALS IN LABORATORY TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL BIOPHARMACEUTICALS IN CUSTOMER PROPRIETARY TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL BIOPHARMACEUTICALS IN COMPENDIAL AND MULTI COMPENDIAL LABORATORY TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 14. GLOBAL BIOPHARMACEUTICALS FOR ONCOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL BIOPHARMACEUTICALS FOR INFLAMMATORY AND INFECTIOUS DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. GLOBAL BIOPHARMACEUTICALS FOR AUTOIMMUNE DISORDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. GLOBAL BIOPHARMACEUTICALS FOR METABOLIC DISORDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. GLOBAL BIOPHARMACEUTICALS FOR CARDIOVASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 19. GLOBAL BIOPHARMACEUTICALS FOR NEUROLOGICAL DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 20. GLOBAL BIOPHARMACEUTICALS FOR OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 21. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 22. NORTH AMERICAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 23. NORTH AMERICAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 24. NORTH AMERICAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY SERVICE, 2022-2030 ($ MILLION)
  • 25. NORTH AMERICAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 26. EUROPEAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 27. EUROPEAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 28. EUROPEAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY SERVICE, 2022-2030 ($ MILLION)
  • 29. EUROPEAN BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 30. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 31. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 32. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY SERVICE, 2022-2030 ($ MILLION)
  • 33. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 34. REST OF THE WORLD BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 35. REST OF THE WORLD BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 36. REST OF THE WORLD BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY SERVICE, 2022-2030 ($ MILLION)
  • 37. REST OF THE WORLD BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL BIOPHARMACEUTICALS MARKET SHARE BY TRANSACTION MODE, 2022 VS 2030 (%)
  • 2. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022 VS 2030 (%)
  • 3. GLOBAL MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL RECOMBINANT GROWTH FACTORS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL PURIFIED PROTEINS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL VACCINES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL HORMONE MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL GENE THERAPIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL OTHER BIOPHARMACEUTICALS PRODUCTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY SERVICE, 2022 VS 2030 (%)
  • 11. GLOBAL BIOPHARMACEUTICALS IN LABORATORY TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL BIOPHARMACEUTICALS IN CUSTOMER PROPRIETARY TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL BIOPHARMACEUTICALS IN COMPENDIAL AND MULTI COMPENDIAL LABORATORY TESTING MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022 VS 2030 (%)
  • 15. GLOBAL BIOPHARMACEUTICALS FOR ONCOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL BIOPHARMACEUTICALS FOR INFLAMMATORY AND INFECTIOUS DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL BIOPHARMACEUTICALS FOR AUTOIMMUNE DISORDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 18. GLOBAL BIOPHARMACEUTICALS FOR METABOLIC DISORDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 19. GLOBAL BIOPHARMACEUTICALS FOR CARDIOVASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 20. GLOBAL BIOPHARMACEUTICALS FOR NEUROLOGICAL DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 21. GLOBAL BIOPHARMACEUTICALS FOR OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 22. GLOBAL BIOPHARMACEUTICALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022 VS 2030 (%)
  • 23. US BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. CANADA BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. UK BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. FRANCE BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. GERMANY BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. ITALY BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. SPAIN BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. REST OF EUROPE BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. INDIA BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 32. CHINA BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 33. JAPAN BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 34. SOUTH KOREA BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 35. REST OF ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 36. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)
  • 37. MIDDLE EAST AND AFRICA BIOPHARMACEUTICALS MARKET SIZE, 2022-2030 ($ MILLION)